Received Nov 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 3 | UNK | — |
Second dose to potential third dose would exceed 11 months; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a patient who did not receive Men B NVS (Bexsero) for prophylaxis. Previously administered products included Bexsero (the first dose of Bexsero administered on 30-OCT-2024) and Bexsero (the second dose of Bexsero administered on 10-DEC-2024). The patient did not receive the 3rd dose of Bexsero. The patient experienced incomplete course of vaccination (Verbatim: Second dose to potential third dose would exceed 11 months). The outcome of the incomplete course of vaccination was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 20-NOV-2025 A Pharmacy resident reported that a patient received 1st dose of Bexsero on 30 OCT 2024 and 2nd on 10 DEC 2024. The reporter asked whether a third dose required now that more than 11 months have elapsed since the earlier doses.